Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 2M | 3M | 508K | 0 |
| Gross Profit | 568K | 11K | 1M | 67K | -109K |
| Operating Income | -12M | -15M | -13M | -7M | -4M |
| EBITDA | -9M | -15M | -6M | -8M | -4M |
| Net Income | -10M | -16M | -6M | -8M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.45
-5.61% today
Window Change
-47.69%
Window
Jan 21, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 101 bars · Jan 21, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pulsenmore Ltd. Ordinary Shares (PLSM) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $3.45 and down 47.7% across the available one-year price window (Jan 21, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of +1409.5%, EPS growth of -57.3%, a dividend yield of 0.0%. What stands out right now is revenue +1409.5%, EPS -57.3%, free cash flow -250.7% with operating margin -30.4% and ROIC -13.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PLSM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLSM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLSM Max Drawdown
-54.89%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLSM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$4.3M
+48.1% YoY
Free Cash Flow
-$3.1M
+64.4% YoY
Revenue Growth
+1409.5%
EPS Growth
-57.3%
Gross Margin
84.2%
Net Margin
-39.6%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 2M | 3M | 508K | 0 |
| Gross Profit | 568K | 11K | 1M | 67K | -109K |
| Operating Income | -12M | -15M | -13M | -7M | -4M |
| EBITDA | -9M | -15M | -6M | -8M | -4M |
| Net Income | -10M | -16M | -6M | -8M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 7M | 4M | 36M | 2M |
| Total Assets | 39M | 50M | 67M | 54M | 3M |
| Total Liabilities | 11M | 11M | 12M | 2M | 1M |
| Shareholder Equity | 27M | 36M | 53M | 49M | 901K |
| Total Debt | 889K | 2M | 2M | 328K | 337K |
| Net Debt | -10M | -5M | -2M | -36M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+64.8% YoY
Capital Expenditures
121K
+51.4% YoY
Free Cash Flow
3M
+64.4% YoY
Key ratios
Gross Margin
84.2%
Operating Margin
-30.4%
Net Margin
-39.6%
ROE
-30.2%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.